Denali Therapeutics Inc. DNLI Enterprise value

Enterprise value at other companies

Eli LillyLLY

$1.12T+51.8%

Regeneron PharmaceuticalsREGN

$65.61B+15.0%

Ultragenyx PharmaceuticalRARE

$1.83B-51.1%

uniQureQURE

$2.82B+376%

PTC TherapeuticsPTCT

$5.2B+77.3%

Viridian Therapeutics, Inc.VRDN

$1.98B+79.5%

FAQ

What is Denali Therapeutics Inc.'s enterprise value?

Denali Therapeutics Inc. (DNLI) reported enterprise value of $3.92B in Q2 2026.

How has Denali Therapeutics Inc.'s enterprise value changed year-over-year?

Denali Therapeutics Inc.'s enterprise value increased by 96.2% year-over-year, from $2B to $3.92B.

What is the long-term trend for Denali Therapeutics Inc.'s enterprise value?

Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s enterprise value has grown at a -24.4% compound annual growth rate (CAGR), from $9.79B to $2.41B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.